Adverse Event Considerations for DARA-VRd in NDMM

Opinion
Video

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Video content above is prompted by the following questions:

  • Please discuss the safety profile of D-VRd and some common AEs seen in clinical practice?
  • What are some considerations/best practices of proactive management of the associated AEs with D-VRd?
Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts in this video
2 experts in this video
Related Content